146 research outputs found
Glycoprotein YKL-40: a novel biomarker of chronic graftvs- host disease activity and severity?
Aim To investigate whether increased YKL-40 levels positively
correlate with graft-vs-host disease (cGVHD) activity
and severity and if YKL-40 could serve as a disease biomarker.
Methods This case-control study was conducted at the
University Hospital Centre Zagreb from July 2013 to October
2015. 56 patients treated with hematopoietic stem
cell transplantation (HSCT) were included: 35 patients with
cGVHD and 21 without cGVHD. There was no difference
between groups in age, sex, median time from transplant
to study enrollment, intensity of conditioning, type of donor,
or source of stem cells. Blood samples were collected
at study enrollment and YKL-40 levels were measured with
ELISA. Disease activity was estimated using Clinicianās Impression
of Activity and Intensity of Immunosuppression
scales and disease severity using Global National Institutes
of Health (NIH) score.
Results YKL-40 levels were significantly higher in cGVHD
patients than in controls (P = 0.003). The difference remained
significant when patients with myelofibrosis were
excluded from the analysis (P = 0.017). YKL-40 level significantly
positively correlated with disease severity (P < 0.001;
correlation coefficient 0.455), and activity estimated using
Clinicianās Impression of Activity (P = 0.016; correlation coefficient
0.412) but not using Intensity of Immunosuppression
(P = 0.085; correlation coefficient 0.296).
Conclusion YKL-40 could be considered a biomarker of
cGVHD severity and activity. However, validation in a larger
group of patients is warranted, as well as longitudinal
testing of YKL-40 levels in patients at risk of developing
cGVHD
Which questionnaires should we use to evaluate quality of life in patients with chronic graft-vs-host disease?
Aim To investigate the ability of two standard quality of life
(QOL) questionnaires ā The Short Form (36-item) Health
Survey (SF-36) and The European Organisation for Research
and Treatment of Cancer Quality of Life Questionnaire-
Core 30 (EORTC QLQ C30) to evaluate QOL in patients with
chronic graft-vs-host disease (cGVHD) graded according to
National Institutes of Health (NIH) consensus criteria.
Methods In this cross-sectional study, QOL was assessed
in patients who underwent allogeneic stem cell transplantation
(allo-SCT) at the University Hospital Centre Zagreb
and were alive and in complete remission for more than
one year after allo-SCT.
Results The study included 58 patients, 38 patients with
cGVHD and 20 controls, patients without cGVHD. Patients
with cGVHD scored according to the NIH criteria had significantly
lower scores of global health status and lower
QOL on all SF-36 subscales and most of QLQ C30 functional
subscales (P < 0.050 for all comparisons). Furthermore,
patients with active cGVHD had significantly lower QOL
scores than patients with inactive cGVHD, and this difference
was most evident in physical functioning subscale of
SF-36 (P = 0.0007) and social functioning subscale of QLQ
C30 (P = 0.009).
Conclusion cGVHD scored according to the NIH criteria
is correlated with patient-reported QOL, particularly in the
physical domains as detected by SF-36. QLQ C30 questionnaire
adds more information on social functioning and
should be used as a valuable tool in the evaluation of social
domains in cGVHD patients
High Incidence of Osteoporosis in a Natural History Cohort of Patients with Moderate to Severe Chronic Graft-Versus-Host Disease and Risk Factor Analysis
Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia
National Cancer Instituteās First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Summary and Recommendations from the Organizing Committee
The National Cancer Instituteās First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation was organized and convened to identify, prioritize, and coordinate future research activities related to relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Each of the Workshopās 6 Working Committees has published individual reports of ongoing basic, translational, and clinical research and recommended areas for future research related to the areas of relapse biology, epidemiology, prevention, and treatment. This document summarizes each committeeās recommendations and suggests 3 major initiatives for a coordinated research effort to address the problem of relapse after allo-HSCT: (1) to establish multicenter correlative and clinical trial networks for basic/translational, epidemiologic, and clinical research; (2) to establish a network of biorepositories for the collection of samples before and after allo-HSCT to aid in laboratory and clinical studies; and (3) to further refine, implement, and study the Workshop-proposed definitions for disease-specific response and relapse and recommendations for monitoring of minimal residual disease. These recommendations, in coordination with ongoing research initiatives and transplantation organizations, provide a research framework to rapidly and efficiently address the significant problem of relapse after allo-HSCT
Predictive Models Using NIH Criteria and Clinical Characteristics Define Diagnosis, Disease Activity and Risk Factors for Chronic Ocular Graft-Versus Host Disease
Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes In Chronic Graft-Versus-Host Disease
The 2005 NIH Consensus Conference recommended assessment of lung function in patients with chronic graft-versus-host disease (GVHD) by both pulmonary function tests (PFTs) and assessment of pulmonary symptoms. We tested whether pulmonary measures were associated with non-relapse mortality (NRM), overall survival (OS) and patient reported outcomes (PRO). Clinician and patient-reported data were collected serially in a prospective, multicenter observational study. Available PFT data were abstracted. Cox regression models were fit for outcomes using a time-varying covariate model for lung function measures and adjusting for patient and transplant characteristics and non-lung chronic GVHD severity. A total of 1591 visits (496 patients) were used in this analysis. The NIH symptom-based lung score was associated with NRM (p=0.02), overall survival (p=0.02), patient-reported symptoms (p<0.001) and functional status (p<0.001). Worsening of NIH symptom-based lung score over time was associated with higher NRM and lower survival. All other measures were not associated with OS or NRM, although some were associated with patient-reported lung symptoms. In conclusion, the NIH symptom-based lung symptom score of 0ā3 is associated with NRM, OS, and PRO measures in patients with chronic GVHD. Worsening of the NIH symptom-based lung score was associated with increased mortality
An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD
B-cell receptor (BCR)-activated B cells contribute to pathogenesis in chronic graft-versus-host disease (cGVHD), a condition manifested by both B-cell autoreactivity and immune deficiency. We hypothesized that constitutive BCR activation precluded functional B-cell maturation in cGVHD. To address this, we examined BCR-NOTCH2 synergy because NOTCH has been shown to increase BCR responsiveness in normal mouse B cells. We conducted ex vivo activation and signaling assays of 30 primary samples from hematopoietic stem cell transplantation patients with and without cGVHD. Consistent with a molecular link between pathways, we found that BCR-NOTCH activation significantly increased the proximal BCR adapter protein BLNK. BCR-NOTCH activation also enabled persistent NOTCH2 surface expression, suggesting a positive feedback loop. Specific NOTCH2 blockade eliminated NOTCH-BCR activation and significantly altered NOTCH downstream targets and B-cell maturation/effector molecules. Examination of the molecular underpinnings of this āNOTCH2-BCR axisā in cGVHD revealed imbalanced expression of the transcription factors IRF4 and IRF8, each critical to B-cell differentiation and fate. All-trans retinoic acid (ATRA) increased IRF4 expression, restored the IRF4-to-IRF8 ratio, abrogated BCR-NOTCH hyperactivation, and reduced NOTCH2 expression in cGVHD B cells without compromising viability. ATRA-treated cGVHD B cells had elevated TLR9 and PAX5, but not BLIMP1 (a gene-expression pattern associated with mature follicular B cells) and also attained increased cytosine guanine dinucleotide responsiveness. Together, we reveal a mechanistic link between NOTCH2 activation and robust BCR responses to otherwise suboptimal amounts of surrogate antigen. Our findings suggest that peripheral B cells in cGVHD patients can be pharmacologically directed from hyperactivation toward maturity
- ā¦